Age Rating
4+
Apps in this category do not contain restricted content.
9+
Apps in this category may contain mild or occasional cartoon, fantasy or real-life violence, as well as occasional or mild adult, sexually suggestive or horrifying content and may not be suitable for children under 9 years of age.
12+
Apps in this category may contain occasional mild indecent language, frequent or intense cartoon or real-life violence, minor or occasional adult or sexually suggestive material, and simulated gambling, and may be for children under 12 years of age.
17+
You must be at least 17 years old to access this App.
Apps in this category may contain frequent and intense offensive language; Frequent and intense cartoon, fantasy or realistic violence: frequent and intense adult, scary and sexually suggestive subjects: as well as sexual content, nudity, tobacco, alcohol and drugs, may not be suitable for children under 17 years of age.
لقطات الشاشة لـ BI News
BI News الملصقBI News الملصق
BI News الملصقBI News الملصق

About BI News

The BI News app allows all Boehringer Ingelheim employees globally to read BI news from Germany and other regions in German and English. News channels can be subscribed to and are listed in the personalized news listing. News can be filtered by channel. With the implemented search function articles can be searched. Push notification can be activated to make sure not to miss any important news.
Show More

تحديث لأحدث إصدار 1.6.3

Last updated on 08/08/2019
الإصدارات القديمة
Bug fixes
Show More
Version History
1.6.3
08/08/2019
Bug fixes
1.6.2
02/08/2019
Bug fixes
1.6.1
27/09/2018
This update contains bug fixes and new features such as Feedback tools, public access to BI Press Releases, an integrated canteen menu for locations in Germany and the addition of HR local news.

BI News FAQ

انقر هنا لمعرفة كيفية تنزيل BI News في بلد أو منطقة محظورة.
تحقق من القائمة التالية لمعرفة الحد الأدنى من المتطلبات BI News.
iPhone
iPad
BI News هي مدعومة على اللغات Dutch, English

بدائل لـ BI News

ربما يعجبك أيضا

أكثر البرنامج من Boehringer Ingelheim Pharma GmbH & Co.KG